University Medical Center Groningen: Breast Neoplasms trials

The registry lists 27 Breast Neoplasms studies with University Medical Center Groningen as lead sponsor. 6 are open to participants now and 0 have results posted.

Early Phase 1 1Phase 1 2Phase 2 6Phase 4 1No phase 18(a study in two phases counts in both)

Studies

Open to participants first, then studies with results posted, then the rest; newest registration first within each.

• Late Scan Time-point Optimalisation of 18F-Fluoroestradiol for the Large Field-of-view (LAFOV) PET/CT Scanner.Not yet recruitingNCT07627269Not applicable
• Standard Follow-up Program (SFP) for Breast Cancer PatientsEnrolling by invitationNCT06429995
• OPTI - DOSE: Optimal Dosing of Oral Anticancer Drugs in Older AdultsNot yet recruitingNCT05949424Phase 4
• Fluorescence Guided Surgery in Breast Cancer - The MARGIN-2 StudyRecruitingNCT05939310Not applicable
• Non Surgical Treatment (Microwave Ablation) of Breast CancerNot yet recruitingNCT05887154Not applicable
• Breast Cancer Long-term Outcomes on Cardiac Functioning: a Longitudinal StudyRecruitingNCT05851053
• Testosterone & Tamoxifen TrialTerminatedNCT05156606Not applicable
• 89Zr-atezolizumab PET Scan and Lobular Breast CancerTerminatedNCT04222426Not applicable
• Implications of MEDIcal Low Dose RADiation Exposure - BReast Cancer Acute Coronary EventsCompletedNCT03211442
• High-dose Chemotherapy With Hematopoietic Stem-cell Rescue for High-risk Breast Cancer: Long-term Follow-upCompletedNCT03087409
• FDHT PET and Bicalutamide in Metastatic Breast CancerCompletedNCT02697032Phase 2
• Fluorescence Guided Surgery in Breast CancerCompletedNCT02583568Phase 1/2
• Late Toxicity in Breast Cancer Patients Treated With Breast-conserving Surgical Procedures and Radiotherapy Using the Simultaneous Integrated Boost TechniqueCompletedNCT02505906
• TOxicity After Radiotherapy in breAst CancEr Survivors (ThORACeS) - A Retrospective Cohort StudyCompletedNCT02471079
• Evaluation of a Physical Activity Program in Overweight Breast Cancer PatientsCompletedNCT02424292
• AR and ER Imaging in Metastatic Breast CancerCompletedNCT01988324Phase 2
• IMaging PAtients for Cancer Drug selecTion - Metastatic Breast CancerActive, not recruitingNCT01957332Not applicable
• Breast Cancer Long-term Outcome of Cardiac DysfunctionCompletedNCT01904331
• Web-based Screening and Tailored SupportCompletedNCT01834521Not applicable
• Clinical Value of 89Zr-trastuzumab PETCompletedNCT01832051Phase 2
• VEGF-targeted Fluorescent Tracer Imaging in Breast CancerCompletedNCT01508572Phase 1
• Molecular Imaging of Fulvestrant Effects on Availability of ER Binding SitesCompletedNCT01377324Phase 2
• Imaging of ER Density to Guide and Improve Tailored Therapy for Acquired Anti-hormonal Resistant Breast CancerCompletedNCT01088477
• Imaging HSP90 Inhibitor AUY922 on VEGF-89ZR-bevacizumab Positron Emission Tomography (PET)CompletedNCT01081613
• 89Zr-trastuzumab PET for Imaging the Effect of HSP90 InhibitionCompletedNCT01081600
• VEGF Early Imaging for Breast CancerCompletedNCT00991978Early Phase 1
• Adjuvant Breast Cancer Study of the Netherlands Working Party for Autotransplantation in Solid TumorsTerminatedNCT00851110Phase 2